Taysha Gene Therapies, Inc. ( (TSHA) ) has released its Q3 earnings. Here is a breakdown of the information Taysha Gene Therapies, Inc. presented to its investors.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focusing on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with a lead program for Rett syndrome.
Taysha Gene Therapies has reported its financial results for the third quarter of 2024, highlighting advancements in its clinical trials and regulatory discussions. The company is making progress in its REVEAL trials for TSHA-102, a therapy for Rett syndrome, with the FDA’s approval for the pivotal product used in these trials.
The company has noted that the high dose of TSHA-102 was well tolerated in patients, with no serious adverse events. There were early clinical improvements in multiple domains, including motor skills and communication, observed in the trials. Taysha is in advanced discussions with the FDA regarding trial design and endpoints, aiming for an expedited development plan for TSHA-102. Financially, the company reported research and development expenses of $14.9 million and a net loss of $25.5 million for the quarter.
Despite the net loss, Taysha has a strong cash position of $157.7 million, expected to support operations into the fourth quarter of 2026. The company remains focused on advancing its clinical programs and is poised for potential regulatory success with TSHA-102, anticipating key trial data in the first half of 2025.
